Tybost is a medicine for treating adults and adolescents from 12 years of age (and over a certain weight) who are infected with HIV-1, a virus that causes acquired immune deficiency syndrome (AIDS).
Tybost does not treat HIV directly but is given to boost the effects of atazanavir or darunavir, which are used with other standard medicines to treat HIV-1.
It contains the active substance cobicistat.
Tybost : EPAR - Medicine overview (PDF/121.03 KB)
First published: 24/10/2013
Last updated: 29/07/2020
Tybost : EPAR - Risk-management-plan summary (PDF/84.43 KB)
First published: 29/07/2020
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Gilead Sciences Ireland UC
|Date of issue of marketing authorisation valid throughout the European Union||
20/05/2020 Tybost - EMEA/H/C/002572 - PSUSA/00010081/201908
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Antivirals for systemic use
Tybost is indicated as a pharmacokinetic enhancer of atazanavir 300 mg once daily or darunavir 800 mg once daily as part of antiretroviral combination therapy in human immunodeficiency virus-1 (HIV-1) infected adults and adolescents aged 12 years and older:
- weighing at least 35 kg co‑administered with atazanavir or
- weighing at least 40 kg co‑administered with darunavir.